Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Nah. . .both quotes are predicting 2 cents or less.
Link as requested for first quote predicting share price on the way to 2 cents:
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=133540444
Predictions to 2 cents (or less). . .as requested:
I don't recall any further FDA enquiries regarding the Norco ANDA.
There is a good chance of that happening. Looking forward to it.
jour_trader. . .I believe you are referring to the CRL that was to be responded to by the end of the year.
jour_trader. . .the Norco ANDA was filed on December 12/2016. I do agree with you though in that we should see an approval hopefully this year.
supwitdacornaz. . . this is the same website I used to check on the listing of Elite on Frankfurt back when the allegation was made in October and it confirmed Elite was not a listing on that exchange. The allegation of Elite trading on Frankfurt was pure BS as usual.
Okay, I will request one more time to provide proof Elite is/was trading in Frankfurt.
And yet proof was requested several times but none was ever provided. LMAO
I was also led to believe that Elite traded on the Frankfurt exchange but that was proven to be complete nonsense.
Thoughts?
Yes, well. . .I have lived long enough to realize that insincere sympathies belong in a place where the sun don't shine.
No sympathy wanted or needed. I have completed my DD on Elite and know what I own. My money. . .my decision. . .my investment to enjoy when I cash out.
Nonsense. More like the shareholders are not buying the BS that is being posted on a daily basis.
Nice try? I just proved (via audited 10K's) the ludicrous allegation Nasrat was dumping millions of shares weekly was false. Yes Elite has diluted shares. Many other R&D pharmas have done the same thing. This is how they finance their R&D programs. Elite continues to conduct research on proposed new ANDA's. New ANDAapprovals/ANDA submissions will be occurring in the coming months.
Agree?. . .absolutely. And yes, it has been shown Nasrat is not selling shares.
Thanks. . .but I will go with the audited 10K's showing Nasrat's holdings have increased by over 4 million shares in a one year period. The allegation he is dumping millions of shares on a weekly basis is laughable nonsense.
Yes. . .it is true Nasrat has not sold any shares. Thanks
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=143229981
jour trader. . .that may be true but there was an earlier post alleging Nasrat was dumping millions of shares weekly through LPC thereby circumventing the form 4's.
Nonsense. Nasrat has not sold any shares. As a matter of fact his share count has increased from the June 14/2017 audited 10K (page 92)(12,642,565 shares) to the June 14/2018 audited 10K (page 72) (16,971,700 shares). As you can see Nasrat's share count has increased by over 4 million.
Nonsense. . .36 or 52 weeks for the Methadone launch? This doesn't even come close to what Nasrat stated during the CC on August 11/2018.
PH4RM4C3UT1C4LS. . .you are most welcome.
And I was told: "he never owned 48 million shares" and that was proven wrong. LOL
Actually he owns more than 48 million shares. According to the last audited 10K, he owns 50,115,539 shares.
Transcript for August 10, 2018 Conference Call:
https://seekingalpha.com/article/4197842-elite-pharmaceuticals-inc-eltp-ceo-nasrat-hakim-q1-2019-results-earnings-call-transcript?part=single
Well, there was that 163 person PIII efficacy study conducted with no adverse affects according to a PR released by Elite. And then there was the small pilot study completed this year and again. . .no adverse affects. I will go with the info provided by Elite unless other sources can prove otherwise.
Good point. That 23 mil study would not have been conducted if the Michael J. Fox Foundation had not funded the preclinical work and PH II study. It was this research that made the connection between Parkinson's and the benefits of isradipine.
Hm. . .could be why they are using isradipine instead of Nilotinib.
Okay. . .but my research on PD studies shows that the CCB (isradipine) seems to be the drug of choice in their efficacy trials. Previous DD posted on this board has indicated Elite and one other pharma are the only two entities in the USA who market the drug. This may bode well for Elite if the drug is deemed to be efficacious in treating of Parkinson's disease symptoms. So. . .I will wait and see how this turns out.
Nasdaq. . . I totally agree with Kennyt. So true. . .and yes ELTP will make shareholders very happy by continuing to execute their business plan and appreciating the share value. ;>)
Nah. . .didn't happen. Thanks
But, but, but none of the investors/shareholders here said that isradipine was the only CCB that could be used in a PD trial but there are studies now being conducted using isradipine exclusively in their efficacy trials.
This is what I found and my scientific team agrees with the study information linked below. LMAO
Well it would not be years and years but there is an application process with the FDA to reintroduce manufacturing/marketing of a discontinued product.
100% correct!!!
And that is what I am looking forward to.
And the funny thing is. . .nobody, at this point in time, outside of Elite knows whether the CTO is for nefarious or legitimate reasons.
So the majority of pharmas, large and small, who have filed CT orders in the past did so for nefarious reasons? Nah. . .I don't think so.
Yep, Elite and many other pharmas have filed CT orders in the past to secure information from their competition.
"Companies would typically seek a confidential treatment order (CTO) to keep information secret that would otherwise put it at a competitive disadvantage if revealed. A company would seek the confidential treatment order by filing a formal request, a confidential treatment request (CTR), with the Securities and Exchange Commission (SEC).
For example, a company may apply for a confidential treatment order by completing a confidential treatment request to keep information regarding a pricing arrangement made with a potential acquisition target secret. This request could be made on the basis that the company's competitors may use this information to go after the target with a more competitive price. Other common items kept confidential include milestone payments and other technical specifications."
Really? I guess all of the other pharmas who have been granted CT orders in the past have something to hide as well. LMAO
Nonsense? Nah. . .see my previous post.